Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
115 hedge funds and large institutions have $76M invested in Clovis Oncology, Inc. in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 52 reducing their positions, and 47 closing their positions.
22% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $10M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less funds holding
Funds holding: 153 → 115 (-38)
47% less capital invested
Capital invested by funds: $144M → $76M (-$68.1M)
58% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 52
72% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.65M |
| 2 |
QF
QVT Financial
New York
|
+$2.35M |
| 3 |
Renaissance Technologies
New York
|
+$1.22M |
| 4 |
E
Ergoteles
New York
|
+$1.04M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$302K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$32.4M |
| 2 |
BlackRock
New York
|
-$7.76M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.97M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.66M |
| 5 |
HF
HRT Financial
New York
|
-$1.42M |
CLVS Hedge Fund Activity: Q2 2022 in Review
115 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2022, worth a combined $76M — down 47% from $144M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of CLVS and 13 opened new positions — a net loss of 34 holders — while 52 trimmed existing stakes and 22 added.
The largest buyer was Millennium Management, adding an estimated $2.65M. The largest seller was Nuveen, exiting entirely with an estimated $32.4M sold.
- 115 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2022, down from 153 in Q1 2022.
- Funds reported $76M of Clovis Oncology, Inc. stock for Q2 2022, down 47% quarter-over-quarter.
- 13 funds opened new Clovis Oncology, Inc. positions in Q2 2022 and 47 closed out, a net change of -34 holders.
- The largest Clovis Oncology, Inc. buyer in Q2 2022 was Millennium Management, an estimated $2.65M added.
- The largest Clovis Oncology, Inc. seller in Q2 2022 was Nuveen, an estimated $32.4M sold.
Based on aggregated 13F filings for Q2 2022.